

Accepted Manuscript

Statin Use and Risk of Skin Cancer

Brian M. Lin, MD, ScM, Wen-Qing Li, PhD, Eunyoung Cho, PhD, Gary C. Curhan, MD, ScD, Abrar A. Qureshi, MD



PII: S0190-9622(17)32749-4

DOI: [10.1016/j.jaad.2017.11.050](https://doi.org/10.1016/j.jaad.2017.11.050)

Reference: YMJD 12154

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 15 June 2017

Revised Date: 15 October 2017

Accepted Date: 7 November 2017

Please cite this article as: Lin BM, Li W-Q, Cho E, Curhan GC, Qureshi AA, Statin Use and Risk of Skin Cancer, *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2017.11.050.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CAPSULE SUMMARY

- Previous studies demonstrated higher keratinocyte carcinoma risk with statin use, but lacked adjustment for important confounders.
- In this study, longer duration of statin use was associated with higher basal cell carcinoma risk in men only.
- The relation between statins and skin cancer risk may differ by sex.

1 **Article type:** Original article

2 **Title:** Statin Use and Risk of Skin Cancer

3 **Authors:** Brian M. Lin MD, ScM^{1,2,3}, Wen-Qing Li PhD^{4,5}, Eunyoung Cho PhD^{2,4,5}, Gary C.
4 Curhan MD, ScD^{2,3,6,7}, Abrar A. Qureshi MD^{2,4,5}

5 ¹Massachusetts Eye and Ear Infirmary, Department of Otolaryngology, Boston, MA 02114,
6 USA

7 ²Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard
8 Medical School, Boston, MA 02115, USA

9 ³Harvard Medical School, Boston, MA 02115, USA

10 ⁴Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, RI
11 02903, USA

12 ⁵Department of Epidemiology, School of Public Health, Brown University, Providence, RI
13 02903, USA

14 ⁶Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115,
15 USA

16 ⁷Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115,
17 USA

18 **Running title:** Statin use and risk of skin cancer

19 **Funding sources:** This work was supported by the National Institutes of Health grants
20 for the Nurses' Health Study (UM1 CA186107 and P01 CA87969) and the Health
21 Professionals Follow-up Study (UM1 CA167552), and the Research Career Development
22 Award of Dermatology Foundation (WL). The sponsors of this study had no role in
23 design and conduct of the study; collection, management, analysis, and interpretation of

24 the data; preparation, review, or approval of the manuscript; and decision to submit the
25 manuscript for publication.

26 **Conflict of Interest Disclosure:** Dr. Qureshi has received honoraria from AbbVie, Amgen, the
27 Centers for Disease Control and Prevention, Janssen, Merck, Pfizer, and Novartis (consultant).
28 Dr. Qureshi is an investigator (without financial compensation) for Sanofi and Regeneron.

29

30 **Correspondence to:**

31 Brian Min-Hann Lin MD, ScM

32 Channing Division of Network Medicine

33 Brigham and Women's Hospital

34 181 Longwood Avenue

35 Boston, MA 02115

36 brian_lin@meei.harvard.edu

37 Phone: 617-525-2683

38 Fax: 617-525-2008

39 **Reprint requests:** Brian Lin

40 **Number of tables:** 5

41 **Number of figures:** 0

42 **Word count (abstract):** 199

43 **Word count (capsule summary):** 50

44 **Word count (text):** 2484

45 **Number of References:** 63

46 **Statement of prior presentation:** This data has not been presented or published elsewhere.

47 **ABSTRACT**

48 **Background:** Statins are among the most commonly used medications in the United States, and
49 statin use is associated with increased risk of basal cell carcinoma (BCC) and squamous cell
50 carcinoma (SCC). However, previous studies are limited by lack of adjustment for important
51 confounders.

52 **Objective:** Examine the relation between statins and skin cancer risk in the Nurses' Health Study
53 and Health Professionals Follow-up Study.

54 **Methods:** Cox proportional hazards regression was used to evaluate associations.

55 **Results:** During follow-up (2000-2010), we documented 10,201 BCC, 1,393 SCC, and 333
56 melanoma cases. History of high cholesterol was not associated with risk of BCC (pooled
57 multivariable-adjusted Hazard ratio (HR)=1.04 [1.00, 1.09], SCC (HR=0.95 [0.85, 1.06]), or
58 melanoma (HR=0.87 [0.64, 1.19]). Statin use was not associated with risk of BCC (HR=1.04
59 [0.99, 1.09]), SCC (HR=1.08 [0.94, 1.24]), or melanoma (HR=1.04 [0.78, 1.38]). There was a
60 trend towards higher BCC risk with longer duration of statin use in men (P -trend=0.003), but not
61 in women (P -trend=0.86).

62 **Limitations:** Lack of treatment data.

63 **Conclusion:** History of high cholesterol was not associated with skin cancer risk. Longer
64 duration of statin use was associated with a trend towards higher BCC risk in men.

65 **Keywords:** Statins; basal cell carcinoma; squamous cell carcinoma; melanoma

66

67

68

69

70 **ABBREVIATIONS**

71 Keratinocyte carcinomas – KCs

72 Squamous cell carcinoma – SCC

73 Basal cell carcinoma – BCC

74 Nurses' Health Study – NHS

75 Health Professionals Follow-up Study – HPFS

76 Multivariable adjusted relative risk – MVRR

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93 INTRODUCTION

94 The incidence of melanoma and keratinocyte carcinomas (KCs) – which are comprised of
95 squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) of the skin – have been
96 increasing in the United States and worldwide, and represent a significant economic burden.¹⁻⁵

97 High cholesterol is also common and affects approximately 13% of adults in the United
98 States.⁶ Several cellular mechanisms that promote altered cholesterol homeostasis have been
99 associated with cancer development,⁷⁻¹² and high cholesterol has been associated with increased
100 risk of certain malignancies including prostate cancer.^{13, 14} However, the potential relation
101 between high cholesterol, KCs, and melanoma has not been previously investigated.

102 Recent estimates from the National Health and Nutrition Examination Survey (NHANES)
103 suggest that 17% of adults in the United States are on a statin medication.¹⁵ In contrast to the
104 lack of studies on the potential relation between skin cancers and high cholesterol, there has been
105 some investigation of the relation between skin cancers and statin (3-hydroxy-3 methylglutaryl
106 coenzyme A inhibitors) use.

107 Although primarily prescribed as cholesterol-lowering medications, statins have been shown to
108 have pleiotropic properties, which include inhibition of tumor cell growth.¹⁶⁻¹⁹ Conversely,
109 statins have also been associated immunosuppression and inhibition of the Ras signaling
110 pathway,²⁰⁻²³ which has been associated with development of KCs.²⁴⁻²⁶ A large prospective study
111 in women demonstrated no significant association between statin use and risk of melanoma.²⁷
112 Previous studies investigating the relation between statin use and KCs found an increased risk of
113 KCs with statin use.²⁸⁻³¹ However, data from these studies are limited by lack of adjustment for
114 UV light exposure²⁸ and lack of malignancy verification and diagnosis date.²⁹

115 We prospectively investigated the relation between high cholesterol, statin use and risk of
116 melanoma, SCC, and BCC in the Nurses' Health Study (NHS) and the Health Professionals
117 Follow-up Study (HPFS) – two cohorts followed by our research group.

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138 MATERIALS AND METHODS

139 Study participants

140 The Nurses' Health Study (NHS) is a prospective cohort of 121,700 registered female nurses
141 aged 30-55 years at study onset in 1976. The Health Professionals' Follow-up Study (HPFS) was
142 established when 51,529 male health professionals aged 40-75 years were enrolled in 1986. In
143 both cohorts, follow-up questionnaires are administered biennially, with an average follow-up
144 rate of greater than 90% of the eligible person-time. This study was approved by the Partners
145 Healthcare Institutional Review Board (1999P011114).

146

147 Ascertainment of high cholesterol

148 On the 1976 and 1978 NHS questionnaires, participants were asked whether they had elevated
149 cholesterol. On the 1980 NHS questionnaire and 1986 HPFS questionnaire, and every two years
150 thereafter, participants were asked whether a clinician had diagnosed them as having elevated
151 cholesterol. We classified participants who answered, "yes" to this question as having a history
152 of high cholesterol from that time onwards. A previous validation study in NHS demonstrated
153 self-reported cases of elevated cholesterol levels are highly reliable, with greater than 85% of
154 reported cases confirmed via review of medical records.³²

155

156 Ascertainment of medication use

157 In 2000, and every two years thereafter, NHS and HPFS participants were asked whether they
158 regularly used statins. We considered women who answered "yes" to have taken the statins for
159 the previous two years. Participants were also asked in 2000 the number of years they used
160 "Statin cholesterol-lowering drugs" prior to the 2000 questionnaire cycle.

161

162 Identification of skin cancer cases

163 Cohort participants reported new cases of skin cancer biennially. Study physicians reviewed
164 participant medical and pathology reports to verify cases of SCC and melanoma. Although
165 medical records were not obtained for cases of reported BCC, previous validation studies
166 performed in these cohorts have demonstrated approximately 90% accuracy in self-reported
167 BCC cases, when confirmed by pathology or medical records.^{32, 33}

168

169 Ascertainment of covariates

170 Covariates were selected based on previously reported related factors for melanoma and KCs.³⁴
171 Factors considered included age, natural hair color, number of skin moles, cumulative ultraviolet
172 flux, skin reaction to prolonged sun exposure during childhood/adolescence, number of lifetime
173 severe or blistering sunburns, family history of melanoma, smoking status, body mass index,
174 citrus consumption,^{35, 36} and physical activity. Data on covariates were obtained from the
175 biennial questionnaires. Dietary factors were derived from semiquantitative food frequency
176 questionnaires mailed to participants every four years. Physical activity was derived from
177 questionnaire information obtained every four years in NHS, and every two years in HPFS.
178 Time-dependent covariates were updated with each questionnaire cycle, when available. In cases
179 where covariate information was missing, information from the previous questionnaire cycle was
180 carried forward.

181

182 Statistical analysis

183 All analyses were performed in a prospective manner using information on high cholesterol
184 and medication use that was collected before the reported case of melanoma or KC. We
185 considered participants who reported high cholesterol in or prior to 2000 (the baseline year of
186 our study) as having a history of high cholesterol. If on a subsequent questionnaire, participants
187 reported having high cholesterol, they were considered to have a history of high cholesterol from
188 that point onward. Duration of statin use was derived by taking the number of years participants
189 reported using statins prior to the 2000 questionnaire cycle, and assigning two additional years of
190 statin use for participants who reported use of statins in any given two-year time period over the
191 follow-up period. Duration of statin use was categorized as <1 year, 1-2 years, 3-4 years, 5-6
192 years, 7-8 years, and >8 years of statin use in our SCC and BCC analyses, and <1 year, 1-2
193 years, 3-4 years, >4 years of statin use in our melanoma analyses. A *P-trend* was utilized to test
194 for an overall trend towards significance by increasing categorical duration of statin use.

195 Multivariable-adjusted relative risks were calculated using Cox proportional hazards regression
196 models. We examined the relation between high cholesterol, statin use, and skin cancer by first
197 examining the relation between history of high cholesterol and skin cancer and subsequently
198 limiting our analysis on statin use and risk of skin cancer to participants with a history of high
199 cholesterol. We performed a separate analysis investigating high cholesterol, statin use, and risk
200 of melanoma that did not exclude participants with a history of SCC or BCC at baseline, and
201 instead adjusted for a history of SCC or history of BCC in the statistical model. We also ran
202 separate models that included adjustment for use of oral steroid medications. We also performed
203 a secondary analysis to evaluate whether the relation between high serum cholesterol, statin use,
204 and risk of skin cancers varied by health screening among participants. Participants were asked
205 each questionnaire cycle whether they underwent a physical examination over the past two years,

206 and we accounted for their responses in our multivariable models. All p-values are two-sided,
207 with 95% confidence intervals calculated for all relative risks. SAS software, version 9.4 (SAS
208 Institute Inc., Cary, North Carolina) was used to perform all statistical analyses.

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229 **RESULTS**

230 Participant characteristics at baseline according to history of high cholesterol and statin use are
231 shown in Table 1. At baseline, 34,376 women (60.0%) and 10,590 men (50.3%) reported a
232 history of high cholesterol. Among participants who reported a history of high cholesterol,
233 11,743 women (34.2%) and 4,341 men (41.0%) reported statin use.

234 During the ten-year follow-up period (2000-2010), 10,201 incident cases of BCC, 1,393
235 incident cases of SCC, and 333 incident cases of melanoma were identified. History of high
236 cholesterol was not associated with risk of BCC (multivariable adjusted relative risk (MVRR) =
237 1.03; 95% confidence interval (CI) = 0.98, 1.08), SCC (MVRR = 0.94; 95% CI = 0.82, 1.08), or
238 melanoma (MVRR = 0.77; 95% CI = 0.58, 1.01) among women (Table 2). Among men, history
239 of high cholesterol was not associated with risk of any skin cancer; the HR [95% CI] was 1.08
240 [1.00, 1.16] for BCC, 0.97 [0.81, 1.16] for SCC, and 1.06 [0.71, 1.57] for melanoma.

241 Among participants with a history of high cholesterol, we did not find significant associations
242 between statin use and risk of BCC, SCC, or melanoma in either women or men (Table 3). In a
243 pooled analysis of the cohorts, the HR [95% CI] was 1.04 [0.99, 1.09] for BCC, 1.08 [0.94, 1.24]
244 for SCC, and 1.04 [0.78, 1.38] for melanoma.

245 Duration of statin use was not associated with risk of BCC (*P-trend* = 0.86), SCC (*P-trend* =
246 0.89), or melanoma (*P-trend* = 0.68) among women (Table 4). Longer duration of statin use was
247 associated with increased risk of BCC (*P-trend* = 0.003) among men. Men who reported statin
248 use for 3-4 years, 5-6 years, and >8 years had an approximately 7%, 12%, and 28% higher risk of
249 BCC, respectively, compared with men who reported <1 year of statin use. Duration of statin use
250 was not associated with risk of SCC (*P-trend* = 0.09) or melanoma among men (*P-trend* = 0.80).

251 In a pooled analysis of the cohorts, longer duration of statin use was not associated with risk of
252 BCC (P -trend = 0.20), SCC (P -trend = 0.28) or melanoma (P -trend = 0.68).

253 An analysis of type of statin use and risk of BCC, SCC, and melanoma (Table 5) demonstrated
254 lower risk of BCC with pravastatin use compared with no statin use in men (MVRR = 0.62; 95%
255 CI = 0.41, 0.93) and a lower risk of BCC with pravastatin use compared with no statin use in
256 men and women combined (MVRR = 0.88; 95% CI = 0.79, 0.99). There was a higher risk of
257 SCC with lovastatin use compared with no statin use in women (MVRR = 1.82; 95% CI = 1.15,
258 2.88), and a higher risk of SCC with lovastatin use compared with no statin use in men and
259 women combined (MVRR = 1.77; 95% CI = 1.20, 2.63).

260 A secondary analysis for melanoma was conducted without excluding participants having a
261 history of BCC or SCC at baseline, but instead adjusting for history of BCC and SCC, and did
262 not materially change the results. Accounting for oral steroid use did not materially change our
263 results. Accounting for health screening among participants did not change our results either
264 (data not shown).

265

266

267

268

269

270

271

272

273

274 **DISCUSSION**

275 History of high cholesterol was not associated with risk of BCC or SCC in women and men.
276 Statin use among participants with a history of high cholesterol was not associated with risk of
277 SCC, BCC, or melanoma, but there was a significant trend towards higher risk of BCC with
278 longer duration of statin use in men.

279 High cholesterol has been associated with increased risk of developing some cancers including
280 prostate cancer.^{13, 14} Cellular mechanisms associated with impaired cholesterol homeostasis have
281 been associated with higher risk of cancer. Inhibition of the ABCA1 gene – which in normal
282 cells mediates transfer of cholesterol across the plasma membrane – has been associated with
283 increased mitochondrial cholesterol, which inhibits the release of mitochondrial apoptosis-
284 promoting molecules, thus facilitating cancer cell survival.⁷ Our data shows no association
285 between high cholesterol and risk of BCC, SCC, or melanoma in HPFS and NHS.

286 Previous studies present conflicting evidence with regards to the association between statin use
287 and KC, reporting positive,²⁸⁻³¹ negative,³⁷⁻³⁹ or no associations.⁴⁰⁻⁴³ A recent large
288 epidemiological study in the Women's Health Initiative demonstrated an increased risk of KC
289 with statin use.⁴⁴ However, their data were limited by the self-reported nature of KCs, and lack
290 of malignancy diagnosis date. Some studies suggest statin use may increase risk of KC due to
291 increased regulatory T cells secondary to immunomodulation,⁴⁵⁻⁴⁷ and statins have been
292 associated with inhibition of the ras signaling pathway,²⁰⁻²² which has been associated with
293 development of KCs.²⁴⁻²⁶ There is increasing evidence that suggests a higher incidence of KCs
294 among immunosuppressed individuals,⁴⁸ and thus, the potential immunosuppressive behavior of
295 statins may serve to increase risk of KCs among statin users.²³ Conversely, statin-induced
296 changes in other cellular pathways have been associated with decreased risk of KC.^{16, 49-54} Our

297 data showed no association between any statin use and risk of BCC, SCC, or melanoma.

298 However, there was a significant trend towards higher risk of BCC with longer duration of statin
299 use in men, but no association between risk of BCC with duration of statin use in women. This
300 finding suggests that there may be differences between the physiological consequences of long-
301 term statin exposure between men and women. Further, it suggests that the potential effects of
302 statin use may be the result of cumulative, long-term exposure to statins.

303 Statins have been shown to have inhibitory effects on human melanoma cells secondary to
304 inhibition of angiogenesis, cell growth,^{18, 19, 55} and promoting apoptosis.^{17, 56} A recent meta-
305 analysis that included data from a number of randomized controlled trials and cohort studies
306 demonstrated no association between statin use and risk of melanoma.⁴² Further, a prospective
307 study in postmenopausal women demonstrated no association between statin use and risk of
308 melanoma.²⁷ In our study, there was no association between statin use or risk of melanoma in
309 men or in women.

310 Different statins have been shown to have varying degrees of solubility in octanol
311 (lipophilicity) and lipid-lowering potency.⁵⁷⁻⁶⁰ A previous study examining the association
312 between statin type and risk of keratinocyte carcinomas demonstrated higher odds of KC with
313 lovastatin use and simvastatin use compared with no statin use in women, which the authors
314 suggested may be related to varying lipophilicity and potency of these drugs.²⁹ In our study, we
315 found a higher risk of SCC with lovastatin use compared with no statin use in men and women,
316 which is consistent with the findings from the previous study. However, we found no association
317 between risk of SCC or BCC with simvastatin use in our study, and a lower risk of BCC with
318 pravastatin use compared with no statin use in men. These findings suggest the association
319 between statin use and risk of BCC may differ by statin type.

320 Our study has limitations. History of high cholesterol and statin use was self-reported, and we
321 lacked information on duration of statin use prior to the baseline year. Although we were able to
322 determine duration of statin use, our study lacked information on statin dose in participants.
323 However, data were prospectively collected over 10 years in this study, and information
324 provided by these cohorts has been shown to be highly reliable in previous studies.^{32, 61-63} We
325 adjusted for many potential confounders in our multivariable models, but given the relatively few
326 cases of melanoma in our cohort, the interpretability of our melanoma analyses may be limited.
327 However, it is worth noting that our findings are consistent with results from a previous large
328 prospective study on the relation between statin use and risk of melanoma.²⁷ We limited our
329 analyses to white participants, given the small sample size and lack of skin cancer cases in other
330 ethnicities.

331 In conclusion, history of high cholesterol was not associated with risk of keratinocyte
332 carcinomas or melanoma, and longer duration of statin use may be associated with higher risk of
333 basal cell carcinoma in men. Our data suggest there may be differences in the physiological
334 consequences of long-term statin exposure and risk of skin cancers between men and women.
335 Individuals using statins long-term may benefit from counseling on the importance of routine
336 self-surveillance and health screening.

337

338

339

340

341

342

343 **ACKNOWLEDGEMENTS**

344 We would like to thank the participants and staff of the Nurses' Health Study and the Health
345 Professionals Follow-up Study for their valuable contributions as well as the following state
346 cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA,
347 ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA,
348 WY.

349

350 **Funding:** This work was supported by the National Institutes of Health grants for the
351 Nurses' Health Study (UM1 CA186107 and P01 CA87969) and the Health Professionals
352 Follow-up Study (UM1 CA167552), and the Research Career Development Award of
353 Dermatology Foundation (WL). The sponsors of this study had no role in design and
354 conduct of the study; collection, management, analysis, and interpretation of the data;
355 preparation, review, or approval of the manuscript; and decision to submit the manuscript
356 for publication.

357

358

359

360

361

362

363

364

365

366 **REFERENCES**

- 367 1. Cancer Statistics Center American Cancer Society. 2016.
- 368 2. Geller AC, Clapp RW, Sober AJ, Gonsalves L, Mueller L, Christiansen CL et al. Melanoma
369 epidemic: an analysis of six decades of data from the Connecticut Tumor Registry. *J Clin*
370 *Oncol* 2013;31:4172-8.
- 371 3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin*
372 2005;55:74-108.
- 373 4. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB et al.
374 Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol*
375 2010;146:283-7.
- 376 5. Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and
377 non-melanoma skin cancer: a systematic review of the literature. *Pharmacoeconomics*
378 2011;29:863-74.
- 379 6. Carroll MD, Kit BK, Lacher DA, Yoon SS. Total and high-density lipoprotein cholesterol in
380 adults: National Health and Nutrition Examination Survey, 2011-2012. *NCHS Data Brief*
381 2013:1-8.
- 382 7. Smith B, Land H. Anticancer activity of the cholesterol exporter ABCA1 gene. *Cell Rep*
383 2012;2:580-90.
- 384 8. Montero J, Morales A, Llacuna L, Lluís JM, Terrones O, Basanez G et al. Mitochondrial
385 cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. *Cancer*
386 *Res* 2008;68:5246-56.
- 387 9. Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM et al. Role of
388 cholesterol in the development and progression of breast cancer. *Am J Pathol*
389 2011;178:402-12.
- 390 10. Vassilev B, Sihto H, Li S, Holtta-Vuori M, Ilola J, Lundin J et al. Elevated levels of StAR-
391 related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer
392 cells: potential mechanisms contributing to progression of HER2-positive breast cancers.
393 *Am J Pathol* 2015;185:987-1000.
- 394 11. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B et al. Functionally
395 recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. *Nat*
396 *Med* 2011;17:1646-51.
- 397 12. Yun SM, Yoon K, Lee S, Kim E, Kong SH, Choe J et al. PPP1R1B-STARD3 chimeric fusion
398 transcript in human gastric cancer promotes tumorigenesis through activation of
399 PI3K/AKT signaling. *Oncogene* 2014;33:5341-7.
- 400 13. Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS. Cholesterol and the
401 risk of grade-specific prostate cancer incidence: evidence from two large prospective
402 cohort studies with up to 37 years' follow up. *BMC Cancer* 2012;12:25.
- 403 14. Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. *Curr Opin*
404 *Pharmacol* 2012;12:751-9.
- 405 15. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of
406 medication use in the ambulatory adult population of the United States: the Slone survey.
407 *JAMA* 2002;287:337-44.
- 408 16. Soma MR, Corsini A, Paoletti R. Cholesterol and mevalonic acid modulation in cell
409 metabolism and multiplication. *Toxicol Lett* 1992;64-65 Spec No:1-15.

- 410 17. Saito A, Saito N, Mol W, Furukawa H, Tsutsumida A, Oyama A et al. Simvastatin inhibits
411 growth via apoptosis and the induction of cell cycle arrest in human melanoma cells.
412 *Melanoma Res* 2008;18:85-94.
- 413 18. Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. The 3-hydroxy-3-
414 methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin
415 inhibit proliferation and invasion of melanoma cells. *BMC Cancer* 2008;8:9.
- 416 19. Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD et al. Atorvastatin prevents
417 RhoC isoprenylation, invasion, and metastasis in human melanoma cells. *Mol Cancer Ther*
418 2003;2:941-8.
- 419 20. Clutterbuck RD, Millar BC, Powles RL, Newman A, Catovsky D, Jarman M et al. Inhibitory
420 effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe
421 combined immunodeficient (SCID) mice. *Br J Haematol* 1998;102:522-7.
- 422 21. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC. Inhibition of Ras
423 farnesylation by lovastatin leads to downregulation of proliferation and migration in
424 primary cultured human glioblastoma cells. *Anticancer Res* 2000;20:2761-71.
- 425 22. DeClue JE, Vass WC, Papageorge AG, Lowy DR, Willumsen BM. Inhibition of cell growth
426 by lovastatin is independent of ras function. *Cancer Res* 1991;51:712-7.
- 427 23. Chow SC. Immunomodulation by statins: mechanisms and potential impact on
428 autoimmune diseases. *Arch Immunol Ther Exp (Warsz)* 2009;57:243-51.
- 429 24. van der Schroeff JG, Evers LM, Boot AJ, Bos JL. Ras oncogene mutations in basal cell
430 carcinomas and squamous cell carcinomas of human skin. *J Invest Dermatol* 1990;94:423-
431 5.
- 432 25. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. Ras
433 gene mutation and amplification in human nonmelanoma skin cancers. *Mol Carcinog*
434 1991;4:196-202.
- 435 26. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. Activated ras genes occur in
436 human actinic keratoses, premalignant precursors to squamous cell carcinomas. *Arch*
437 *Dermatol* 1995;131:796-800.
- 438 27. Jagtap D, Rosenberg CA, Martin LW, Pettinger M, Khandekar J, Lane D et al. Prospective
439 analysis of association between use of statins and melanoma risk in the Women's Health
440 Initiative. *Cancer* 2012;118:5124-31.
- 441 28. Arnspang S, Pottgard A, Friis S, Clemmensen O, Andersen KE, Hallas J et al. Statin use
442 and risk of nonmelanoma skin cancer: a nationwide study in Denmark. *Br J Cancer*
443 2015;112:153-6.
- 444 29. Wang A, Stefanick ML, Kapphahn K, Hedlin H, Desai M, Manson JA et al. Relation of
445 statin use with non-melanoma skin cancer: prospective results from the Women's Health
446 Initiative. *Br J Cancer* 2016;114:314-20.
- 447 30. Mascitelli L, Pezzetta F, Goldstein MR. The epidemic of nonmelanoma skin cancer and
448 the widespread use of statins: Is there a connection? *Dermatoendocrinol* 2010;2:37-8.
- 449 31. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and
450 meta-analysis. *Eur J Cancer* 2008;44:2122-32.
- 451 32. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B et al. Validation of
452 questionnaire information on risk factors and disease outcomes in a prospective cohort
453 study of women. *Am J Epidemiol* 1986;123:894-900.

- 454 33. van Dam RM, Huang Z, Giovannucci E, Rimm EB, Hunter DJ, Colditz GA et al. Diet and
455 basal cell carcinoma of the skin in a prospective cohort of men. *Am J Clin Nutr*
456 2000;71:135-41.
- 457 34. Li WQ, Cho E, Weinstock MA, Mashfiq H, Qureshi AA. Epidemiological Assessments of
458 Skin Outcomes in the Nurses' Health Studies. *Am J Public Health* 2016:e1-e7.
- 459 35. Wu S, Cho E, Feskanich D, Li WQ, Sun Q, Han J et al. Citrus consumption and risk of basal
460 cell carcinoma and squamous cell carcinoma of the skin. *Carcinogenesis* 2015;36:1162-8.
- 461 36. Wu S, Han J, Feskanich D, Cho E, Stampfer MJ, Willett WC et al. Citrus Consumption and
462 Risk of Cutaneous Malignant Melanoma. *J Clin Oncol* 2015;33:2500-8.
- 463 37. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase
464 inhibitors and the risk of cancer: a nested case-control study. *Arch Intern Med*
465 2000;160:2363-8.
- 466 38. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in
467 users of statins. *J Clin Oncol* 2004;22:2388-94.
- 468 39. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R et al. Analyses of cancer
469 data from three ezetimibe trials. *N Engl J Med* 2008;359:1357-66.
- 470 40. Asgari MM, Tang J, Epstein EH, Jr., Chren MM, Warton EM, Quesenberry CP, Jr. et al.
471 Statin use and risk of basal cell carcinoma. *J Am Acad Dermatol* 2009;61:66-72.
- 472 41. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A et al. Incidence of
473 cancer and statin usage--record linkage study. *Int J Cancer* 2010;126:279-84.
- 474 42. Li X, Wu XB, Chen Q. Statin use is not associated with reduced risk of skin cancer: a
475 meta-analysis. *Br J Cancer* 2014;110:802-7.
- 476 43. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized
477 clinical trials. *Am J Med* 2001;110:716-23.
- 478 44. Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT et al. Statin use and
479 all-cancer survival: prospective results from the Women's Health Initiative. *Br J Cancer*
480 2016.
- 481 45. Curiel TJ. Tregs and rethinking cancer immunotherapy. *J Clin Invest* 2007;117:1167-74.
- 482 46. Jang TJ. Prevalence of Foxp3 positive T regulatory cells is increased during progression
483 of cutaneous squamous tumors. *Yonsei Med J* 2008;49:942-8.
- 484 47. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G et
485 al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
486 *Atherosclerosis* 2008;197:829-39.
- 487 48. Rangwala S, Tsai KY. Roles of the immune system in skin cancer. *Br J Dermatol*
488 2011;165:953-65.
- 489 49. Cooper MK, Wassif CA, Krakowiak PA, Taipale J, Gong R, Kelley RI et al. A defective
490 response to Hedgehog signaling in disorders of cholesterol biosynthesis. *Nat Genet*
491 2003;33:508-13.
- 492 50. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation
493 of Fas and apoptosis. *Biochem Biophys Res Commun* 2004;320:165-9.
- 494 51. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK
495 pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
496 *Cancer Res* 2004;64:6461-8.
- 497 52. Tang JY, So PL, Epstein EH, Jr. Novel Hedgehog pathway targets against basal cell
498 carcinoma. *Toxicol Appl Pharmacol* 2007;224:257-64.

- 499 53. Corcoran RB , Scott MP. Oxysterols stimulate Sonic hedgehog signal transduction and
500 proliferation of medulloblastoma cells. *Proc Natl Acad Sci U S A* 2006;103:8408-13.
- 501 54. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R et al. Inhibition of the
502 hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med* 2009;361:1164-72.
- 503 55. Sora MK, Kruszewski AA, Stoklosa T, Czyzyk J, Lasek W, Malejczyk J et al. Synergistic
504 antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin. *Arch*
505 *Immunol Ther Exp (Warsz)* 1994;42:269-74.
- 506 56. Minichsdorfer C , Hohenegger M. Autocrine amplification loop in statin-induced
507 apoptosis of human melanoma cells. *Br J Pharmacol* 2009;157:1278-90.
- 508 57. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins:
509 an update. *Fundam Clin Pharmacol* 2005;19:117-25.
- 510 58. Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of
511 dyslipidaemia. *Expert Opin Investig Drugs* 2002;11:125-41.
- 512 59. Jones P, Kafonek S, Laurora I , Hunninghake D. Comparative dose efficacy study of
513 atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with
514 hypercholesterolemia (the CURVES study). *Am J Cardiol* 1998;81:582-7.
- 515 60. Duncan RE, El-Sohemy A , Archer MC. Statins and the risk of cancer. *JAMA*
516 2006;295:2720; author reply 1-2.
- 517 61. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB , Willett WC.
518 Reproducibility and validity of an expanded self-administered semiquantitative food
519 frequency questionnaire among male health professionals. *Am J Epidemiol* 1992;135:1114-
520 26; discussion 27-36.
- 521 62. Wolf AM, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Corsano KA et al.
522 Reproducibility and validity of a self-administered physical activity questionnaire. *Int J*
523 *Epidemiol* 1994;23:991-9.
- 524 63. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB , Willett WC. Validity of self-
525 reported waist and hip circumferences in men and women. *Epidemiology* 1990;1:466-73.
526
- 527

Table 1. Baseline Characteristics of Participants According to History of High Cholesterol and Statin use in Women in the Nurses' Health Study (NHS) and in Men in the Health Professionals Follow-up Study (HPFS)

	History of High Cholesterol		Statin Use	
	No	Yes	No	Yes
Women in NHS (2000)				
No. of participants	22,862	34,376	45,119	12,119
Age, years ^a	64.1(7.1)	66.1(6.9)	64.9(7.1)	67.0(6.8)
Family history of melanoma, %	6.9	7.3	7.2	7.2
Red/blonde hair, %	14.8	14.4	14.6	14.5
Painful burn/blisters reaction as a child/adolescent, %	12.8	13.8	13.1	14.5
No. of blistering sunburns	8.2(6.9)	8.5(6.8)	8.4(6.9)	8.6(6.9)
Use of sunscreen, %	23.9	23.0	23.3	23.5
Annual UV flux ($\times 10^{-4}$ RB count)	123.3(25.4)	123.6(26.0)	123.8(25.9)	122.5(25.4)
Body mass index (kg/m ²)	26.2(5.4)	27.4(5.4)	26.6(5.4)	28.2(5.4)
Physical activity level (metabolic-equivalents hrs/wk)	18.3(23.0)	16.2(21.2)	17.5(21.8)	15.5(22.8)
Current smoking, %	10.8	9.2	9.8	9.8
Menopausal status, %	97.3	97.7	97.5	97.8
Current postmenopausal hormones use, ^b %	48.5	50.1	49.8	48.4
Total energy intake (kcal/d)	1741.6(534.0)	1722.1(531.9)	1738.3(533.9)	1696.5(527.3)
Alcohol intake (g/d)	5.4(9.3)	4.7(9.0)	5.1(9.2)	4.3(8.5)
Total citrus intake (serving/d)	0.8(0.6)	0.8(0.6)	0.8(0.6)	0.8(0.6)
Statin use, %	1.8	33.6	-	-

History of high cholesterol, %	-	-	50.6	96.9
Men in HPFS (2000)				
No. of participants	10,453	10,590	16,304	4,739
Age, years ^a	64.0(8.7)	64.6(8.3)	64.0(8.6)	65.4(8.1)
Family history of melanoma, %	4.5	4.9	4.7	4.9
Red/blonde hair, %	12.9	11.9	12.6	11.5
Painful burn/blisters reaction as a child/adolescent, %	21.7	21.8	22.1	20.8
No. of blistering sunburns	12.6(12.1)	12.6(11.9)	12.8(12.1)	12.2(11.7)
Use of sunscreen, %	58.5	60.3	58.9	60.8
Annual UV flux ($\times 10^{-4}$ RB count)	129.4(27.3)	129.5(27.5)	129.5(27.4)	129.1(27.5)
Body mass index (kg/m ²)	25.6(5.1)	26.2(4.9)	25.7(5.0)	26.5(4.9)
Physical activity level (metabolic-equivalents hrs/wk)	35.2(43.3)	30.7(36.3)	33.7(40.7)	30.3(36.8)
Current smoking, %	4.5	4.1	4.5	3.7
Total energy intake (kcal/d)	2019.7(545.1)	1970.5(532.4)	2013.4(543.3)	1930.7(518.0)
Alcohol intake (g/d)	10.4(13.8)	11.0(13.9)	10.7(14.0)	10.8(13.2)
Total citrus intake (serving/d)	1.0(0.7)	0.9(0.7)	0.9(0.7)	0.9(0.7)
Statin use, %	3.9	40.6	-	-
History of high cholesterol, %	-	-	38.4	91.7

Values are means (SD), or percentages and have been standardized to the age distribution of the study population.

^a Values are not age adjusted.

^b Percentages among postmenopausal women

Table 2. Age- and Multivariable-Adjusted Relative Risks of Skin Cancer According to History of High Cholesterol, Nurses' Health Study (NHS, 2000-2010) and Health Professionals Follow-Up Study (HPFS, 2000-2010)

	No. of Cases	Person-Years	Age-Adjusted RR	95% CI	Multivariable-Adjusted RR*	95% CI
Basal cell carcinoma						
NHS						
No history of high cholesterol	2,215	159,784	1.00	Reference	1.00	Reference
History of high cholesterol	5,072	318,951	1.02	0.97, 1.07	1.03	0.98, 1.08
HPFS						
No history of high cholesterol	1,212	73,058	1.00	Reference	1.00	Reference
History of high cholesterol	1,702	93,196	1.06	0.99, 1.14	1.08	1.00, 1.16
Pooled[†]						
No history of high cholesterol	3,427	232,842	1.00	Reference	1.00	Reference
History of high cholesterol	6,774	412,147	1.03	0.99, 1.08	1.04	1.00, 1.09
Squamous cell carcinoma						
NHS						
No history of high cholesterol	298	160,676	1.00	Reference	1.00	Reference
History of high cholesterol	586	321,044	0.90	0.78, 1.04	0.94	0.82, 1.08
HPFS						
No history of high cholesterol	222	74,096	1.00	Reference	1.00	Reference
History of high cholesterol	287	94,658	0.95	0.80, 1.13	0.97	0.81, 1.16
Pooled[†]						
No history of high cholesterol	520	234,772	1.00	Reference	1.00	Reference
History of high cholesterol	873	415,702	0.92	0.82, 1.03	0.95	0.85, 1.06
Melanoma						
NHS						
No history of high cholesterol	87	160,872	1.00	Reference	1.00	Reference
History of high cholesterol	141	321,436	0.78	0.60, 1.03	0.77	0.58, 1.01
HPFS						
No history of high cholesterol	44	74,255	1.00	Reference	1.00	Reference
History of high cholesterol	61	94,839	1.07	0.73, 1.59	1.06	0.71, 1.57
Pooled[†]						

No history of high cholesterol	131	235,127	1.00	Reference	1.00	Reference
History of high cholesterol	202	416, 275	0.89	0.66, 1.20	0.87	0.64, 1.19

*Adjusted for family history of melanoma (yes vs. no), natural hair color (red, blonde, light brown, dark brown, black), number of arm moles (0, 1-2, 3-9, ≥ 10), sunburn susceptibility as a child/adolescent (none/some redness, burn, painful burn/blisters), number of lifetime blistering sunburns (0, 1-4, 5-9, ≥ 10), cumulative UV flux since baseline (quintiles), body mass index (<25.0 , 25.0-29.9, 30.0-34.9, ≥ 35.0 kg/m²), physical activity (quintiles), smoking status (never, past, or current), total energy intake (quintiles), alcohol (0, 0.1-4.9, 5.0-9.9, 10.0-19.9, ≥ 20.0 g/d), and citrus intake (quintiles). Analyses for women were also adjusted for menopausal status and postmenopausal hormone use.

† The multivariate-adjusted hazard ratios from each cohort were combined with meta-analytic methods using random effects model.

Table 3. Age- and Multivariable-Adjusted Relative Risks of Skin Cancer Among Women and Men with a History of High Cholesterol, According to Statin use, Nurses' Health Study (NHS, 2000-2010) and Health Professionals Follow-Up Study (HPFS, 2000-2010)

	No. of Cases	Person-Years	Age-Adjusted RR	95% CI	Multivariable-Adjusted RR*	95% CI
Basal cell carcinoma						
NHS						
No statin use	2,646	176,403	1.00	Reference	1.00	Reference
Statin use	2,426	142,548	1.01	0.95, 1.07	1.03	0.97, 1.09
HPFS						
No statin use	742	43,444	1.00	Reference	1.00	Reference
Statin use	960	49,752	1.07	0.97, 1.18	1.07	0.97, 1.18
Pooled[†]						
No statin use	3,388	219,847	1.00	Reference	1.00	Reference
Statin use	3,386	192,300	1.03	0.97, 1.08	1.04	0.99, 1.09
Squamous cell carcinoma						
NHS						
No statin use	319	177,555	1.00	Reference	1.00	Reference
Statin use	267	143,489	0.99	0.84, 1.17	1.03	0.87, 1.22
HPFS						
No statin use	117	44,097	1.00	Reference	1.00	Reference
Statin use	170	50,561	1.15	0.91, 1.46	1.18	0.93, 1.50
Pooled[†]						
No statin use	436	221,652	1.00	Reference	1.00	Reference
Statin use	437	194,050	1.04	0.90, 1.20	1.08	0.94, 1.24
Melanoma						
NHS						
No statin use	73	177,778	1.00	Reference	1.00	Reference
Statin use	68	143,657	1.11	0.79, 1.55	1.11	0.79, 1.56
HPFS						
No statin use	30	44,173	1.00	Reference	1.00	Reference
Statin use	31	50,666	0.94	0.56, 1.58	0.89	0.52, 1.50
Pooled[†]						

No statin use	103	221,951	1.00	Reference	1.00	Reference
Statin use	99	194,323	1.06	0.80, 1.40	1.04	0.78, 1.38

*Adjusted for family history of melanoma (yes vs. no), natural hair color (red, blonde, light brown, dark brown, black), number of arm moles (0, 1-2, 3-9, ≥ 10), sunburn susceptibility as a child/adolescent (none/some redness, burn, painful burn/blisters), number of lifetime blistering sunburns (0, 1-4, 5-9, ≥ 10), cumulative UV flux since baseline (quintiles), body mass index (<25.0 , 25.0-29.9, 30.0-34.9, ≥ 35.0 kg/m²), physical activity (quintiles), smoking status (never, past, or current), total energy intake (quintiles), alcohol (0, 0.1-4.9, 5.0-9.9, 10.0-19.9, ≥ 20.0 g/d), and citrus intake (quintiles). Analyses for women were also adjusted for menopausal status and postmenopausal hormone use.

† The multivariate-adjusted hazard ratios from each cohort were combined with meta-analytic methods using random effects model.

Table 4. Age- and Multivariable-Adjusted Relative Risks of Skin Cancer Among Women and Men with a History of High Cholesterol, According to Duration of Statin use, Nurses' Health Study (NHS, 2000-2010) and Health Professionals Follow-Up Study (HPFS, 2000-2010)

	No. of Cases	Person-Years	Age-Adjusted RR	95% CI	Multivariable-Adjusted RR*	95% CI
Basal cell carcinoma						
NHS						
<1 year statin use	2,322	158,556	1.00	Reference	1.00	Reference
1-2 years statin use	788	50,908	1.02	0.94, 1.11	1.05	0.96, 1.14
3-4 years statin use	658	41,587	0.99	0.91, 1.08	1.01	0.93, 1.11
5-6 years statin use	491	26,515	1.04	0.94, 1.15	1.07	0.96, 1.18
7-8 years statin use	393	20,693	1.02	0.92, 1.14	1.05	0.94, 1.17
>8 years statin use	420	20,692	0.93	0.83, 1.03	0.95	0.85, 1.06
					<i>P-trend = 0.86</i>	
HPFS						
<1 year statin use	660	39,363	1.00	Reference	1.00	Reference
1-2 years statin use	235	13,890	0.98	0.84, 1.14	0.98	0.85, 1.14
3-4 years statin use	265	14,140	1.06	0.92, 1.23	1.07	0.93, 1.24
5-6 years statin use	191	9,473	1.12	0.95, 1.32	1.12	0.95, 1.32
7-8 years statin use	138	7,067	1.07	0.89, 1.30	1.07	0.89, 1.30
>8 years statin use	213	9,263	1.28	1.08, 1.50	1.28	1.08, 1.50
					<i>P-trend = 0.003</i>	
Pooled[†]						
<1 year statin use	2,982	197,918	1.00	Reference	1.00	Reference
1-2 years statin use	1,023	64,798	1.02	0.95, 1.10	1.03	0.96, 1.11
3-4 years statin use	923	55,727	1.04	0.96, 1.12	1.05	0.97, 1.13
5-6 years statin use	682	35,989	1.09	1.00, 1.18	1.09	1.00, 1.19
7-8 years statin use	531	27,761	1.05	0.96, 1.15	1.05	0.95, 1.15
>8 years statin use	633	29,955	1.04	0.95, 1.14	1.03	0.94, 1.13
					<i>P-trend = 0.20</i>	
Squamous cell carcinoma						
NHS						
<1 year statin use	294	159,586	1.00	Reference	1.00	Reference

1-2 years statin use	77	51,278	0.80	0.62, 1.02	0.85	0.66, 1.09
3-4 years statin use	85	41,849	1.04	0.82, 1.33	1.10	0.86, 1.40
5-6 years statin use	55	26,686	1.04	0.77, 1.40	1.09	0.81, 1.47
7-8 years statin use	40	20,828	0.94	0.67, 1.32	0.96	0.69, 1.35
>8 years statin use	35	20,817	0.84	0.59, 1.21	0.86	0.60, 1.24
<i>P-trend = 0.89</i>						
HPFS						
<1 year statin use	102	39,943	1.00	Reference	1.00	Reference
1-2 years statin use	39	14,082	1.02	0.71, 1.48	1.04	0.72, 1.51
3-4 years statin use	40	14,374	1.02	0.71, 1.48	1.07	0.74, 1.55
5-6 years statin use	50	9,636	1.83	1.28, 2.61	1.89	1.32, 2.70
7-8 years statin use	20	7,187	0.91	0.56, 1.50	0.95	0.58, 1.56
>8 years statin use	36	9,435	1.28	0.86, 1.92	1.31	0.87, 1.96
<i>P-trend = 0.09</i>						
Pooled[†]						
<1 year statin use	396	199,529	1.00	Reference	1.00	Reference
1-2 years statin use	116	65,360	0.87	0.71, 1.07	0.90	0.73, 1.11
3-4 years statin use	125	56,224	1.07	0.87, 1.30	1.08	0.88, 1.32
5-6 years statin use	105	36,322	1.36	1.09, 1.70	1.35	1.08, 1.68
7-8 years statin use	60	28,015	1.00	0.76, 1.31	0.97	0.73, 1.28
>8 years statin use	71	30,252	1.10	0.84, 1.43	1.04	0.79, 1.35
<i>P-trend = 0.28</i>						
Melanoma						
NHS						
<1 year statin use	68	159,792	1.00	Reference	1.00	Reference
1-2 years statin use	25	51,315	1.13	0.71, 1.78	1.13	0.71, 1.80
3-4 years statin use	18	41,907	0.95	0.56, 1.60	0.96	0.57, 1.62
>4 years statin use	30	68,422	0.92	0.59, 1.45	0.93	0.59, 1.47
<i>P-trend = 0.68</i>						
HPFS						
<1 year statin use	26	40,008	1.00	Reference	1.00	Reference
1-2 years statin use	11	14,109	1.24	0.61, 2.53	1.22	0.60, 2.49

3-4 years statin use	6	14,397	0.67	0.27, 1.64	0.67	0.27, 1.66
>4 years statin use	18	26,326	1.11	0.58, 2.12	1.02	0.52, 1.97
<i>P-trend = 0.80</i>						
Pooled[†]						
<1 year statin use	94	199,800	1.00	Reference	1.00	Reference
1-2 years statin use	36	65,424	1.18	0.80, 1.73	1.18	0.80, 1.74
3-4 years statin use	24	56,304	0.89	0.56, 1.40	0.89	0.56, 1.39
>4 years statin use	48	94,747	1.00	0.70, 1.44	0.97	0.67, 1.41
<i>P-trend = 0.68</i>						

*Adjusted for family history of melanoma (yes vs. no), natural hair color (red, blonde, light brown, dark brown, black), number of arm moles (0, 1-2, 3-9, ≥ 10), sunburn susceptibility as a child/adolescent (none/some redness, burn, painful burn/blisters), number of lifetime blistering sunburns (0, 1-4, 5-9, ≥ 10), cumulative UV flux since baseline (quintiles), body mass index (< 25.0 , 25.0-29.9, 30.0-34.9, ≥ 35.0 kg/m²), physical activity (quintiles), smoking status (never, past, or current), total energy intake (quintiles), alcohol (0, 0.1-4.9, 5.0-9.9, 10.0-19.9, ≥ 20.0 g/d), and citrus intake (quintiles). Analyses for women were also adjusted for menopausal status and postmenopausal hormone use.

[†] The multivariate-adjusted hazard ratios from each cohort were combined with meta-analytic methods using random effects model

Table 5. Age- and Multivariable-Adjusted Relative Risks of Skin Cancer Among Women and Men with a History of High Cholesterol, According to Type of Statin use, Nurses' Health Study (NHS, 2004-2010) and Health Professionals Follow-Up Study (HPFS, 2004-2010)

	No. of Cases	Person-Years	Age-Adjusted RR	95% CI	Multivariable-Adjusted RR*	95% CI
Basal cell carcinoma						
NHS						
No statin use	1583	87,512	1.00	Reference	1.00	Reference
Lovastatin use	117	5,797	1.06	0.88, 1.28	1.04	0.86, 1.26
Simvastatin use	394	17,803	1.02	0.91, 1.14	1.03	0.92, 1.16
Rosuvastatin use	198	10,288	1.07	0.92, 1.24	1.08	0.93, 1.25
Pravastatin use	337	22,202	0.92	0.82, 1.04	0.94	0.83, 1.06
Atorvastatin use	576	28,877	1.02	0.92, 1.12	1.03	0.94, 1.14
HPFS						
No statin use	360	19,484	1.00	Reference	1.00	Reference
Lovastatin use	29	1,406	1.06	0.72, 1.55	1.01	0.69, 1.47
Simvastatin use	197	8,637	1.15	0.97, 1.37	1.15	0.96, 1.37
Rosuvastatin use	19	1,439	0.75	0.47, 1.20	0.75	0.47, 1.20
Pravastatin use	25	2,124	0.62	0.41, 0.93	0.62	0.41, 0.93
Atorvastatin use	291	14,261	1.11	0.95, 1.30	1.11	0.95, 1.30
Pooled[†]						
No statin use	1,943	106,996	1.00	Reference	1.00	Reference
Lovastatin use	146	7,203	1.06	0.89, 1.25	1.03	0.87, 1.22
Simvastatin use	591	26,440	1.10	1.00, 1.20	1.09	1.00, 1.20
Rosuvastatin use	217	11,727	1.00	0.87, 1.15	1.01	0.88, 1.16
Pravastatin use	362	24,325	0.86	0.77, 0.96	0.88	0.79, 0.99
Atorvastatin use	867	43,138	1.07	0.99, 1.16	1.07	0.99, 1.16
Squamous cell carcinoma						
NHS						
No statin use	162	88,126	1.00	Reference	1.00	Reference
Lovastatin use	21	5,825	1.87	1.18, 2.95	1.82	1.15, 2.88
Simvastatin use	27	17,919	0.88	0.58, 1.33	0.91	0.60, 1.37

Rosuvastatin use	23	10,362	1.13	0.73, 1.77	1.17	0.75, 1.83
Pravastatin use	45	22,343	0.99	0.70, 1.40	1.03	0.73, 1.45
Atorvastatin use	44	29,080	0.86	0.61, 1.21	0.89	0.63, 1.26
HPFS						
No statin use	56	19,795	1.00	Reference	1.00	Reference
Lovastatin use	7	1,432	1.52	0.68, 3.39	1.55	0.70, 3.44
Simvastatin use	27	8,789	1.01	0.63, 1.60	1.02	0.64, 1.62
Rosuvastatin use	4	1,452	0.86	0.31, 2.39	0.91	0.33, 2.52
Pravastatin use	11	2,141	1.85	0.97, 3.53	1.78	0.92, 3.42
Atorvastatin use	52	14,512	1.29	0.88, 1.89	1.31	0.89, 1.92
Pooled[†]						
No statin use	218	107,920	1.00	Reference	1.00	Reference
Lovastatin use	28	7,257	1.83	1.23, 2.71	1.77	1.20, 2.63
Simvastatin use	54	26,708	0.95	0.75, 1.37	0.94	0.69, 1.27
Rosuvastatin use	27	11,814	1.05	0.71, 1.60	1.15	0.77, 1.73
Pravastatin use	56	24,484	1.07	0.78, 1.42	1.16	0.85, 1.56
Atorvastatin use	96	43,592	1.11	0.88, 1.43	1.04	0.81, 1.33
<hr/>						
Melanoma						
NHS						
No statin use	40	88,241	1.00	Reference	1.00	Reference
Lovastatin use	3	5,839	1.11	0.34, 3.61	1.10	0.34, 3.59
Simvastatin use	6	17,939	0.70	0.29, 1.68	0.73	0.30, 1.74
Rosuvastatin use	7	10,376	1.41	0.62, 3.20	1.46	0.64, 3.33
Pravastatin use	15	22,364	1.41	0.76, 2.62	1.39	0.74, 2.60
Atorvastatin use	12	29,105	0.96	0.50, 1.87	0.96	0.49, 1.88
HPFS						
No statin use	13	19,835	1.00	Reference	1.00	Reference
Lovastatin use	2	1,437	2.01	0.44, 9.15	1.88	0.38, 9.37
Simvastatin use	6	8,805	1.05	0.40, 2.80	1.05	0.38, 2.89
Rosuvastatin use	0	1,458	0.00	0.00, 0.00	0.00	0.00, 0.00
Pravastatin use	2	2,145	1.50	0.33, 6.73	1.53	0.32, 7.24
Atorvastatin use	7	14,545	0.88	0.35, 2.22	0.76	0.29, 1.99

Pooled[†]							
No statin use	53	108,077	1.00	Reference	1.00	Reference	
Lovastatin use	5	7,276	1.32	0.53, 3.32	1.30	0.51, 3.30	
Simvastatin use	12	26,744	0.87	0.46, 1.64	0.87	0.46, 1.64	
Rosuvastatin use	7	11,834	1.20	0.54, 2.66	1.22	0.54, 2.71	
Pravastatin use	17	24,510	1.37	0.78, 2.41	1.39	0.79, 2.45	
Atorvastatin use	19	43,650	0.93	0.55, 1.58	0.90	0.52, 1.54	

*Adjusted for family history of melanoma (yes vs. no), natural hair color (red, blonde, light brown, dark brown, black), number of arm moles (0, 1-2, 3-9, ≥ 10), sunburn susceptibility as a child/adolescent (none/some redness, burn, painful burn/blisters), number of lifetime blistering sunburns (0, 1-4, 5-9, ≥ 10), cumulative UV flux since baseline (quintiles), body mass index (<25.0, 25.0-29.9, 30.0-34.9, ≥ 35.0 kg/m²), physical activity (quintiles), smoking status (never, past, or current), total energy intake (quintiles), alcohol (0, 0.1-4.9, 5.0-9.9, 10.0-19.9, ≥ 20.0 g/d), and citrus intake (quintiles). Analyses for women were also adjusted for menopausal status and postmenopausal hormone use.

[†]The multivariate-adjusted hazard ratios from each cohort were combined with meta-analytic methods using random effects model.